Contineum Therapeutics, Inc. (NASDAQ:CTNM) Receives Consensus Recommendation of "Buy" from Analysts

Contineum Therapeutics, Inc. (NASDAQ:CTNM - Get Free Report) has received a consensus rating of "Buy" from the six ratings firms that are presently covering the firm, Marketbeat.com reports. Five research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 12 month target price among analysts that have covered the stock in the last year is $24.80.

CTNM has been the topic of a number of analyst reports. Royal Bank of Canada restated an "outperform" rating and issued a $31.00 price target on shares of Contineum Therapeutics in a research note on Thursday, January 9th. Robert W. Baird cut their price target on shares of Contineum Therapeutics from $32.00 to $16.00 and set an "outperform" rating for the company in a report on Friday, March 7th. Jones Trading assumed coverage on shares of Contineum Therapeutics in a report on Thursday, March 13th. They set a "buy" rating and a $23.00 price objective on the stock. Finally, Morgan Stanley restated an "overweight" rating and set a $25.00 target price on shares of Contineum Therapeutics in a research report on Friday, March 7th.

Institutional Investors Weigh In On Contineum Therapeutics

Large investors have recently added to or reduced their stakes in the business. FMR LLC lifted its holdings in shares of Contineum Therapeutics by 115.4% in the third quarter. FMR LLC now owns 696,927 shares of the company's stock valued at $13,339,000 after purchasing an additional 373,327 shares in the last quarter. BNP Paribas Financial Markets lifted its stake in Contineum Therapeutics by 1,248.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 6,743 shares of the company's stock valued at $129,000 after buying an additional 6,243 shares in the last quarter. State Street Corp grew its holdings in Contineum Therapeutics by 23.7% during the 3rd quarter. State Street Corp now owns 113,566 shares of the company's stock valued at $2,174,000 after buying an additional 21,760 shares during the last quarter. Barclays PLC increased its position in Contineum Therapeutics by 248.6% during the third quarter. Barclays PLC now owns 8,308 shares of the company's stock worth $158,000 after buying an additional 5,925 shares in the last quarter. Finally, Franklin Resources Inc. raised its holdings in shares of Contineum Therapeutics by 130.9% in the third quarter. Franklin Resources Inc. now owns 1,447,550 shares of the company's stock worth $27,706,000 after acquiring an additional 820,542 shares during the last quarter.

Contineum Therapeutics Trading Down 2.9 %

Shares of Contineum Therapeutics stock traded down $0.12 on Monday, reaching $4.01. 66,573 shares of the stock were exchanged, compared to its average volume of 77,178. The firm has a market capitalization of $103.75 million and a PE ratio of -0.82. Contineum Therapeutics has a 1-year low of $3.91 and a 1-year high of $22.00. The business has a fifty day moving average price of $6.97 and a two-hundred day moving average price of $12.16.

Contineum Therapeutics Company Profile

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS).